Beyond the Diagnosis: The Family That Challenged a Rare Disease

By Global Health & Science Desk
Published September 2026

Main Facts

In the quiet academic hub of Iowa City, an ordinary evening in 1992 set into motion a scientific odyssey that would challenge the boundaries of modern medical research. Six-year-old Jenna Smith, bathing in her family home, noticed something terrifying: the bathwater around her waist had turned a reddish-pink. What initially felt to a child like a shameful secret—the fear of having urinated in the tub—unraveled into a life-altering medical mystery.

Jenna was diagnosed with dense deposit disease (DDD), an ultra-rare, incurable renal disorder affecting roughly one to three people per million. Caused by a catastrophic malfunction in the body’s ancient complement system—an evolutionary immune mechanism that mistakenly acts like a runaway train—the disease attacks the kidneys’ tiny filtering units, known as glomeruli.

For Jenna’s parents, Richard Smith, an ear, nose, and throat (ENT) physician and researcher at the University of Iowa, and Lynne Lanning, a former lawyer and nurse, the diagnosis marked the beginning of a relentless campaign. Confronted by a medical establishment that largely ignored conditions with insufficient patient populations, the Smith family refused to accept a terminal outlook. Their journey transformed not only Jenna’s life but also injected momentum into an obscure corner of nephrology research through grassroots fundraising, global collaboration, and sheer familial resilience.

Chronology of a Medical Crisis

1992: The Discovery and the Diagnosis

• The Bathtub Incident: Six-year-old Jenna Smith notices blood in her urine for the first time in the spring of 1992. Out of embarrassment, she initially tells no one, not even her identical twin sister, Jessica, or her parents.
• The ER Visits: When the hematuria persists, Jenna informs her mother. Her father, Dr. Richard Smith, rushes her to the emergency room in Iowa City. Local doctors are completely baffled.
• The Cincinnati Trek: Following advice from a pediatric nephrologist in Houston, Richard and Lynne drive nearly 500 miles to Cincinnati Children’s Hospital Medical Center. Doctors there provide the chilling diagnosis: dense deposit disease, with no known cure and a high statistical probability of progressing to total renal failure.

1993–1997: Progression and Mounting Hurdles

• Physical Toll: Jenna begins heavy treatments of prednisone and blood-pressure medication, causing significant water retention, fatigue, and stunted growth. Despite her illness, she continues dancing, performing in The Nutcracker while resting backstage between scenes.
• Kidney Failure: In less than a year after diagnosis—at the end of her first-grade year—Jenna’s kidneys fail. Rather than letting nurses instruct her parents, seven-year-old Jenna insists on learning how to operate her own peritoneal dialysis machine.
• The Dead End: In early 1997, after a disheartening consultation at the University of Minnesota, a specialist bluntly tells Richard and Lynne that no one is studying the disease, and no treatments will materialize for decades. Driving back to Iowa City, Lynne poses the pivotal question: Maybe they would have to be that unforeseen something.

Supporting Data and Medical Context

Understanding the gravity of Jenna’s condition requires examining the mechanics of rare diseases within the modern pharmaceutical landscape:

• Prevalence: Dense deposit disease is classified as an ultra-rare disorder, occurring in approximately 1 to 3 individuals per million.
• The Complement System Malfunction: The complement system is an evolutionary defense mechanism designed to rapidly deploy proteins to fight foreign pathogens without needing prior exposure. In DDD patients, this system loses its regulatory checks, causing proteins to accumulate destructively inside the renal glomeruli.
• Prognosis Timeline: Historically, approximately 50% of diagnosed patients progress to end-stage renal disease within a decade of diagnosis. Jenna reached this critical threshold in under 12 months.
• The Orphan Disease Dilemma: Approximately 1 in 10 Americans suffers from a rare disease. Because patient cohorts are exceptionally small, traditional pharmaceutical companies routinely bypass these conditions, viewing research and development investments as economically unviable. Consequently, families are frequently left to pioneer their own advocacy networks.

Official Responses and Institutional Realities

The path of the Smith family exposed structural limitations within major medical charities and research institutions during the late 1990s:

• The National Kidney Foundation: Seeking to fund research directly, Richard and Lynne helped organize "Dressage in the Heartland," a regional equestrian fundraiser that successfully raised upwards of $10,000. However, institutional policies at the time prohibited donors from earmarking funds for specific, hyper-rare conditions like dense deposit disease. (Note: The foundation has since updated its policies to allow condition-specific contributions.)
• The Medical Establishment: Mainstream specialists offered a sobering assessment of the medical landscape in the 1990s, noting a severe deficit of clinical trials, targeted funding, or academic interest in complement-mediated kidney disorders.
• Institutional Adaptation: Despite initial bureaucratic resistance, the advocacy spearheaded by families like the Smiths gradually forced academic medical centers to re-evaluate how rare renal pathologies are prioritized, paving the way for modern translational research initiatives.

Implications for Modern Science and Patient Advocacy

The story of Jenna Smith and her family challenges long-held cultural tropes about scientific progress. As historian and narrative accounts suggest, scientific history has historically mythologized the "lone genius"—the solitary researcher toiling away in isolation, prioritizing lab work over domestic life.

The battle against dense deposit disease proved that breakthroughs often require a vastly different ecosystem:

1. Collaborative Family Networks: Richard balancing a grueling schedule as a pediatric otolaryngologist and hearing-loss researcher while mentally dissecting his daughter’s nephrological dilemma at 3:00 AM; Lynne cultivating an intentionally connected, creative, and joyful household despite the shadow of chronic illness.
2. Grassroots Mobilization: Transforming riding stables, local communities, and academic contacts into a distributed web of advocates.
3. Redefining Patient Agency: Jenna herself—insisting at age seven on managing her own dialysis machine—demonstrated that patients, particularly pediatric ones, can become active participants in their treatment protocols rather than passive recipients of care.

Ultimately, the collective efforts originating from that Iowa City home helped alter the trajectory of an obscure medical field. By refusing to let bureaucratic hurdles or statistical odds dictate their daughter’s future, the Smith family demonstrated that the cure for medical isolation is often forged not in corporate boardrooms, but through the relentless, collective will of a family refusing to give up.